Neurovascular Transduction During Exercise in Chronic Kidney Disease



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease, Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - 75
Updated:11/18/2018
Start Date:October 2016
End Date:November 2021
Contact:Jeanie Park, MD
Email:jeanie.park@emory.edu
Phone:404-727-2525

Use our guide to learn which trials are right for you!

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have
poor exercise capacity and to explore what causes an increase in blood pressure during
exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).
This study will also test whether or not regular exercise on a bicycle and/or treatment with
6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures
during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a
disease called phenylketonuria, but it is not currently FDA approved for blood pressure or
exercise capacity in people with CKD.

The major problem addressed in this study is to understand mechanisms underlying poor
exercise capacity in patients with chronic kidney disease (CKD). Prior research has found
that CKD patients have an exaggerated increase in blood pressure during certain forms of
exercise that could contribute to exercise dysfunction as well as cardiovascular disease.
This study will test the mechanisms underlying this exaggerated blood pressure response, as
well as the potential benefits of simple measures such as exercise training on a stationary
bicycle, and treatment with 6R-BH4, a drug that is currently FDA-approved for the treatment
of phenylketonuria, but has been shown to have beneficial effects on vascular health in
patients with kidney disease. This study will also examine the effects of exercise with
histidine and beta-alanine supplementation. Histidine and beta-alanine are two
over-the-counter supplements commonly used to enhance sports performance in athletes.

Prior to the intervention portion of this study, the researchers will measure how much the
vein constricts in response to adrenaline in CKD patients versus controls. The study will
also measure muscle pH, and muscle oxygenation during exercise in CKD patients and controls.

The intervention portion of the study will test whether aerobic exercise training with and
without 6R-BH4, or with and without histidine and beta-alanine supplementation might help
muscle pH and adrenaline levels, vascular reactivity, muscle oxygenation, and the exaggerated
blood pressure response during exercise in CKD patients. Participants will be randomized
using a 2x2 factorial design to exercise training (ET) with 6R-BH4, ET with placebo,
stretching (control condition to exercise) with 6R-BH4, and stretching with placebo.
Participants will undergo exercise training on a stationary bicycle, or stretching exercises,
3 times per week for 6-14 weeks (depending on availability of the participant).

Inclusion Criteria for Chronic Kidney Disease Patients:

- Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular
filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification
of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation

- Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3
months

- Does not exercise regularly (defined as exercising less than 20 minutes twice per
week)

- Willing and able to cooperate with the study protocol

Inclusion Criteria for Control Study Participants:

- Does not exercise regularly (defined as exercising less than 20 minutes twice per
week)

- Willing and able to cooperate with the study protocol

Exclusion Criteria:

- severe CKD (eGFR<15 cc/minute)

- ongoing drug or alcohol abuse

- diabetic neuropathy

- any serious systemic disease that might influence survival

- severe anemia with hgb level <9 g/dL

- clinical evidence of congestive heart failure or ejection fraction below 35%

- symptomatic heart disease determined by prior electrocardiogram, stress test, and/or
history

- treatment with central alpha agonists (clonidine)

- uncontrolled hypertension with BP greater than 170/100 mm Hg

- low blood pressure with BP less than 100/50

- pregnancy or plans to become pregnant

- current treatment with monoamine oxidase (MAO) inhibitors

- inability to exercise on a stationary bicycle
We found this trial at
3
sites
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Jeanie Park, MD
Phone: 404-727-7762
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Principal Investigator: Jeanie Park, MD
Phone: 404-727-7762
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Jeanie Park, MD
Phone: 404-727-7762
?
mi
from
Decatur, GA
Click here to add this to my saved trials